Several studies demonstrated that IKZF1 deletions are significantly associated with an increased relapse rate and adverse events and are correlated with poor outcome in patients with Ph+ ALL [27–29]. The gene discussed is IKZF1; the disease is acute lymphoblastic leukemia.